Table 1 Summary of demographics and baseline characteristics (NCT04450004)
From: Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
CoVLP 3.75 µg | CoVLP 7.5 µg | CoVLP 15 µg | All | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Unadjuvanted | Adjuvanted with CpG 1018 | Adjuvanted with AS03 | Unadjuvanted | Adjuvanted with CpG 1018 | Adjuvanted with AS03 | Unadjuvanted | Adjuvanted with CpG 1018 | Adjuvanted with AS03 | ||
Participants | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 180 |
Sex, n (%) | ||||||||||
Male | 9 (45.0) | 10 (50.0) | 5 (25.0) | 10 (50.0) | 8 (40.0) | 8 (40.0) | 7 (35.0) | 10 (50.0) | 11 (55.0) | 78 (43.3) |
Female | 11 (55.0) | 10 (50.0) | 15 (75.0) | 10 (50.0) | 12 (60.0) | 12 (60.0) | 13 (65.0) | 10 (50.0) | 9 (45.0) | 102 (56.7) |
Race, n (%) | ||||||||||
White | 18 (90.0) | 20 (100.0) | 20 (100.0) | 20 (100.0) | 18 (90.0) | 19 (95.0) | 20 (100.0) | 18 (90.0) | 19 (95.0) | 172 (95.6) |
Black or African American | 1 (5.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 1 (5.0) | 1 (5.0) | 4 (2.2) |
Asian | 1 (5.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.0) | 1 (5.0) | 0 (0.0) | 1 (5.0) | 0 (0.0) | 4 (2.2) |
Ethnicity, n (%) | ||||||||||
Hispanic/Latinx | 0 (0.0) | 2 (10.0) | 0 (0.0) | 1 (5.0) | 3 (15.0) | 1 (5.0) | 0 (0.0) | 1 (5.0) | 0 (0.0) | 9 (5.0) |
Age at vaccination | ||||||||||
Mean ± s.d. | 34.9 ± 8.3 | 35.3 ± 11.0 | 34.7 ± 9.1 | 35.6 ± 8.0 | 32.4 ± 9.5 | 37.2 ± 7.8 | 34.1 ± 9.6 | 32.0 ± 9.0 | 32.7 ± 9.1 | 34.3 ± 9.0 |
Median (range) | 35 (18–49) | 36 (18–53) | 36 (19–49) | 36 (20–50) | 31 (19–52) | 37 (21–55) | 31.5 (22–54) | 30 (19–51) | 32.5 (18–52) | 34 (18–55) |
